Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence di Sushentsev, N, Hamm, G, Richings, J, McLean, MA, Menih, IH, Ayyappan, V, Mills, IG, Warren, AY, Gnanapragasam, VJ, Barry, ST, Goodwin, RJA, Gallagher, FA, Barrett, T

Independence of HIF1a and androgen signaling pathways in prostate cancer di Tran, MGB, Bibby, BAS, Yang, L, Lo, F, Warren, AY, Shukla, D, Osborne, M, Hadfield, J, Carroll, T, Stark, R, Scott, H, Ramos-Montoya, A, Massie, C, Maxwell, P, West, CML, Mills, IG, Neal, DE

Metabolic imaging across scales reveals distinct prostate cancer phenotypes di Sushentsev, N, Hamm, G, Flint, L, Birtles, D, Zakirov, A, Richings, J, Ling, S, Tan, JY, McLean, MA, Ayyappan, V, Horvat Menih, I, Brodie, C, Miller, JL, Mills, IG, Gnanapragasam, VJ, Warren, AY, Barry, ST, Goodwin, RJA, Barrett, T, Gallagher, FA

Hyperpolarised 13C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer di Sushentsev, N, McLean, MA, Warren, AY, Benjamin, AJV, Brodie, C, Frary, A, Gill, AB, Jones, J, Kaggie, JD, Lamb, BW, Locke, MJ, Miller, JL, Mills, IG, Priest, AN, Robb, FJL, Shah, N, Schulte, RS, Graves, MJ, Gnanapragasam, VJ, Brindle, KM, Barrett, T, Gallagher, FA

The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates di Buhigas, C, Warren, AY, Leung, W-K, Whitaker, HC, Luxton, HJ, Hawkins, S, Kay, J, Butler, A, Xu, Y, Woodcock, DJ, Merson, S, Frame, FM, Sahli, A, Abascal, F, Martincorena, I, Bova, GS, Foster, CS, Campbell, P, Maitland, NJ, Neal, DE, Massie, CE, Lynch, AG, Eeles, RA, Cooper, CS, Wedge, DC, Brewer, DS, Mills, IG

HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer di Ross-Adams, H, Ball, S, Lawrenson, K, Halim, S, Russell, R, Wells, C, Strand, SH, Ørntoft, TF, Larson, M, Armasu, S, Massie, CE, Asim, M, Mortensen, MM, Borre, M, Woodfine, K, Warren, AY, Lamb, AD, Kay, J, Whitaker, H, Ramos-Montoya, A, Murrell, A, Sørensen, KD, Fridley, BL, Goode, EL, Gayther, SA, Masters, J, Neal, DE, Mills, IG

Molecular subgroup of primary prostate cancer presenting with metastatic biology. di Walker, SM, Knight, LA, McCavigan, AM, Logan, GE, Berge, V, Sherif, A, Pandha, H, Warren, AY, Davidson, C, Uprichard, A, Blayney, JK, Price, B, Jellema, GL, Steele, CJ, Svindland, A, McDade, SS, Eden, CG, Foster, C, Mills, IG, Neal, DE, Mason, MD, Kay, EW, Waugh, DJ, Harkin, DP, Watson, RW, Clarke, NW, Kennedy, RD

The ProtecT trial: Analysis of the patient cohort, baseline risk stratification and disease progression di Young, GJ, Davis, M, Turner, EL, Martin, RM, Goepel, JR, Varma, M, Griffiths, DF, Grigor, K, Mayer, N, Warren, AY, Bhattarai, S, Dormer, J, Mason, M, Staffurth, J, Walsh, E, Rosario, DJ, Catto, JW, Neal, DE, Donovan, JL, Hamdy, FC, Bollina, P, Doble, A, Doherty, A, Gillatt, D, Gnanapragasam, V, Hughes, O, Kockelbergh, R, Kynaston, H, Paul, A, Paez, E, Rowe, E

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. di Asim, M, Tarish, F, Zecchini, HI, Sanjiv, K, Gelali, E, Massie, CE, Baridi, A, Warren, AY, Zhao, W, Ogris, C, McDuffus, L-A, Mascalchi, P, Shaw, G, Dev, H, Wadhwa, K, Wijnhoven, P, Forment, JV, Lyons, SR, Lynch, AG, O'Neill, C, Zecchini, VR, Rennie, PS, Baniahmad, A, Tavaré, S, Mills, IG, Galanty, Y, Crosetto, N, Schultz, N, Neal, D, Helleday, T